Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LAS100977 · 1 trial · 1 indication
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min) Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1 At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected
| Arm | Type | Description |
|---|---|---|
| Arm #2 | EXPERIMENTAL | Single dose, double blind treatment period |
| Arm #3 | EXPERIMENTAL | Single dose, double blind treatment period |
| Arm #4 | EXPERIMENTAL | Single dose, double blind treatment period |
| Arm #5 | ACTIVE_COMPARATOR | Single dose, double blind treatment period |
| Arm #6 | PLACEBO_COMPARATOR | Single dose, double blind treatment period |
| Arm #1 | EXPERIMENTAL | Single dose, double blind treatment period |
| Name | Type | Description |
|---|---|---|
| LAS100977 | DRUG | Dry powder inhalation,Once daily, single dose |
| Reference | DRUG | Dry powder inhalation (capsule),single dose |
| Placebo | DRUG | Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose |
Inclusion Criteria: 1. Males and non-pregnant, non-lactating females aged 40 or older. 2. Patients with a clinical diagnosis of COPD, according to the GOLD guidelines and stable airway obstruction. 3. Patients with a post-salbutamol FEV1 equal to or greater than 30% of the predicted value and less ...
LAS100977 is an investigational small molecule being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
LAS100977 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is in Phase 2 clinical trials for Chronic Obstructive Pulmonary Disease (COPD).
LAS100977 is in Phase 2 clinical development. It is an investigational drug for Chronic Obstructive Pulmonary Disease (COPD) and has not yet been approved for commercial use.
LAS100977 has one completed Phase 2 clinical trial, identified as NCT01425814. This was a single-dose study assessing the efficacy and safety of four doses of LAS100977 in patients with Chronic Obstructive Pulmonary Disease (COPD). The trial enrolled 87 participants in Germany.
LAS100977 is the primary name for this investigational drug. No alternative names have been reported for this compound in its clinical development program.